Long-term complete remission of metastatic adrenocortical carcinoma. 2023

Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
Department of Endocrinology, "Fundación Jiménez-Diaz" University Hospital, Madrid, Spain.

OBJECTIVE To report a rare case of a metastatic adrenocortical carcinoma (ACC) that achieve a complete and a long-term remission. METHODS AAC is a rare and aggressive tumor, with a high risk of recurrence and that present metastases in 21% of cases at diagnosis. Treatment of advanced ACC is challenging, mitotane is the only available adrenolytic treatment, with modest and unpredictable responses. Response rates to systemic chemotherapy are not encouraging. We describe the case of a 39-year-old woman with a metastatic ACC, that achieve a complete and long-term remission after chemotherapy, mitotane treatment and surgery of primary tumor and liver metastases. CONCLUSIONS A complete remission of a metastatic adrenocortical carcinoma is possible in some rare cases after a multimodal treatment.

UI MeSH Term Description Entries
D008939 Mitotane A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression. o,p-DDD,ortho,para-DDD,Chloditan,Chlodithane,Khloditan,Lysodren,Mytotan,ortho,para DDD
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000306 Adrenal Cortex Neoplasms Tumors or cancers of the ADRENAL CORTEX. Adrenocortical Cancer,Cancer of Adrenal Cortex,Adrenal Cortex Cancer,Cancer of the Adrenal Cortex,Neoplasms, Adrenal Cortex,Adrenal Cortex Cancers,Adrenal Cortex Neoplasm,Adrenocortical Cancers,Cancer, Adrenal Cortex,Cancer, Adrenocortical,Cancers, Adrenal Cortex,Cancers, Adrenocortical,Neoplasm, Adrenal Cortex
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D018268 Adrenocortical Carcinoma A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM. Carcinoma, Adrenal Cortical,Carcinoma, Adrenocortical,Adrenal Cortical Carcinoma,Adrenal Cortical Carcinomas,Adrenocortical Carcinomas,Carcinomas, Adrenal Cortical,Carcinomas, Adrenocortical
D018931 Antineoplastic Agents, Hormonal Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic

Related Publications

Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
March 2023, JGH open : an open access journal of gastroenterology and hepatology,
Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
May 1992, Presse medicale (Paris, France : 1983),
Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
March 2008, Urology,
Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
January 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
February 2018, Hormones & cancer,
Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
January 1994, Experimental and clinical endocrinology,
Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
December 2019, Journal of gastrointestinal and liver diseases : JGLD,
Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
January 1997, Diagnostic and therapeutic endoscopy,
Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
October 2002, The Journal of clinical endocrinology and metabolism,
Jersy Cárdenas-Salas, and Beatriz Castelo, and Rita María Regojo, and Juan Antonio González-Sanchez, and Cristina Álvarez-Escolá
January 2005, Oncology,
Copied contents to your clipboard!